公开(公告)号：US20070135457A1

公开(公告)日：2007-06-14

申请号：US10595766

申请日：2004-12-06

申请人： Thomas Beyer ,  Robert Chambers ,  Kelvin Lam ,  Mei Li ,  Andrew Morrell ,  David Thompson

发明人： Thomas Beyer ,  Robert Chambers ,  Kelvin Lam ,  Mei Li ,  Andrew Morrell ,  David Thompson

IPC分类号： A61K31/519 ,  C07D487/02

CPC分类号： A61K31/519 ,  A61K31/00 ,  C07D471/04

摘要： The invention provides compounds of formula (I) prodrugs thereof, and the pharmaceutically acceptable salts of the compounds or prodrugs, wherein n, X, and Y are as defined herein; pharmaceutical compositions thereof; combinations thereof; and uses thereof.

摘要翻译： 本发明提供式（I）的前药化合物及其化合物或前药的药学上可接受的盐，其中n，X和Y如本文所定义; 其药物组合物; 其组合; 及其用途。

公开(公告)号：US08728812B2

公开(公告)日：2014-05-20

申请号：US12989284

申请日：2009-04-22

申请人： Shuibing Chen ,  Douglas A. Melton ,  Malgorzata Borowiak ,  Julia Lamenzo ,  Stuart L. Schreiber ,  Lee F. Peng ,  Lance Davidow ,  Kelvin Lam ,  Lee L. Rubin

发明人： Shuibing Chen ,  Douglas A. Melton ,  Malgorzata Borowiak ,  Julia Lamenzo ,  Stuart L. Schreiber ,  Lee F. Peng ,  Lance Davidow ,  Kelvin Lam ,  Lee L. Rubin

IPC分类号： C12N5/00 ,  C12N5/071 ,  C12N5/02

CPC分类号： C12N5/0678 ,  C12N5/0606 ,  C12N5/0676 ,  C12N2501/115 ,  C12N2501/119 ,  C12N2501/16 ,  C12N2501/385 ,  C12N2501/415 ,  C12N2501/42 ,  C12N2501/727 ,  C12N2501/998 ,  C12N2501/999 ,  C12N2506/02

摘要： Certain embodiments disclosed herein are directed to a method of producing pancreatic cells or pancreatic cell precursors by exposing human embryonic stem cells to an effective amount of at least one compound listed in Table I to differentiate the human embryonic stem cells into the pancreatic cells or the pancreatic cell precursors. Kits and pancreatic cell lines produced using the methods are also described.

摘要翻译： 本文公开的某些实施例涉及通过将人胚胎干细胞暴露于有效量的表I所列的至少一种化合物来产生胰腺细胞或胰腺细胞前体的方法，以将人胚胎干细胞分化成胰腺细胞或胰腺细胞 细胞前体。 还描述了使用这些方法生产的试剂盒和胰腺细胞系。

公开(公告)号：US20110099158A1

公开(公告)日：2011-04-28

申请号：US12607745

申请日：2009-10-28

申请人： Richard Kevin Magnuson ,  Stephen J. Siwek ,  Kelvin Lam ,  Rashmi Rekha Sahoo ,  A.V.S.S.N.S. Sudhakar ,  David Andrew Tootill

发明人： Richard Kevin Magnuson ,  Stephen J. Siwek ,  Kelvin Lam ,  Rashmi Rekha Sahoo ,  A.V.S.S.N.S. Sudhakar ,  David Andrew Tootill

IPC分类号： G06F17/30

CPC分类号： G06Q10/06 ,  G06Q10/04

摘要： A system and method for automatically detecting, reporting, and tracking conflicts in a change management system is provided. In particular, the system and method described herein may be used to identify potential conflicts associated with resources and schedules involved in a proposed change to an information technology infrastructure. A conflict analysis engine may analyze a change order that includes planned changes to an information technology infrastructure to identify potential conflicts associated with the change order that includes the planned changes to the information technology infrastructure. The potential conflicts may then be added to a conflicts list for the change order and a workflow may be created to manage resolving the potential conflicts. Thus, in response to resolving the potential conflicts, the planned changes may be deployed within the information technology infrastructure.

摘要翻译： 提供了一种用于自动检测，报告和跟踪变更管理系统中的冲突的系统和方法。 特别地，本文描述的系统和方法可以用于识别与信息技术基础设施的建议改变中涉及的资源和时间表相关联的潜在冲突。 冲突分析引擎可以分析包括对信息技术基础设施的计划更改的变更顺序，以识别与包含计划的信息技术基础设施变更的变更顺序相关的潜在冲突。 然后可能将潜在的冲突添加到更改顺序的冲突列表中，并且可以创建工作流来管理解决潜在的冲突。 因此，为了解决潜在的冲突，计划的变更可能部署在信息技术基础设施中。

公开(公告)号：US06274596B1

公开(公告)日：2001-08-14

申请号：US09413405

申请日：1999-10-06

申请人： Kelvin Lam ,  Vincent Boyd ,  Yi Bin Xiang

发明人： Kelvin Lam ,  Vincent Boyd ,  Yi Bin Xiang

IPC分类号： A61K3147

CPC分类号： A61K31/496 ,  A61K31/00 ,  A61K31/473

摘要： Disclosed are pharmaceutical compositions and formulations comprising benzoquinoline derivatives having the formula (I) to (V), wherein formula (I) is: X is selected from the group consisting of O, S, CH2, CH2-CH2, C═O or NRB; Y is C or N; R1, R2, R3 and R4 are independently selected from the group consisting of hydrogen, halogen, linear or branched chain lower alky, alkenyl, alkynyl, alkoxy or acyl; X-RA and R3, or R3 and R4, are optionally linked together to form a C3-C4 alkylene bridge, where X is CH2 or C═O; provided that: when X is NRB, then (a) RB is hydrogen, and RA is a linear or branched chain lower alkyl, aryl, heteroaryl, cycloalkyl or cycloalkenyl optionally interrupted by at least one heteroatom, said alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or cycloalkenyl being optionally substituted singly or plurally by at least one of a linear or branched chain lower alkyl, alkenyl, alkynyl, acyl, alkoxy, or cycloalkyl optionally interrupted by at least one heteroatom and optionally substituted by at least one linear or branched chain lower alkyl, alkenyl, alkynyl, acyl, or alkoxy, or a linear or branched chain lower alkyl mono- or dialkylamino, (linear or branched chain lower alkyl N-mono- or N,N-dialkylamino)(lower alkyl), (linear or branched chain lower alkyl N-mono- or N,N-dialkyl)carbamyl, aryl or heteroaryl; or (b) X, RA and RB together form a ring system comprising from about five to about twelve linked carbon atoms, said system being optionally interrupted by at least one heteroatom, optionally mono- or polyunsaturated and optionally substituted singly or plurally by at least one of a linear or branched chain lower alkyl, alkenyl, alkynyl, acyl, or alkoxy, a linear or branched chain lower alkyl N-mono- or N,N-dialkylamino, (linear or branched chain lower alkyl N-mono- or N,N-dialkylarnino)(lower alkyl), halogen, cyano, trifluoromethyl, nitro, aryl or heteroaryl; and when X is O, S, CH2, CH2-CH2 or C═O, then (a) RA is hydrogen or a linear or branched chain lower alkyl, alkenyl, alkynyl, aryl or heteroaryl, said alkyl, alkenyl, alkynyl, aryl or heteroaryl being optionally substituted singly or plurally by at least one of a linear or branched chain lower alkyl, alkenyl, alkynyl, acyl, or alkoxy, a linear or branched chain lower alkyl N-mono- or N,N-dialkylamino, (linear or branched chain lower alkyl N-mono- or N,N-dialkylamino)(lower alkyl), halogen, cyano, trifluoromethyl, nitro, aryl or heteroaryl; and (b) R3 is a linear or branched chain lower alkyl substituted by hydroxyphenyl or linear or branched chain lower alkoxyphenyl singly or plurally substituted by CH2NRCRD wherein N, RC and RD together form a ring system comprising from about five to about twelve linked carbon atoms, said system being optionally interrupted by at least one heteroatom, optionally mono- or polyunsaturated and optionally substituted singly or plurally by at least one of a linear or branched chain lower alkyl, acyl, or alkoxy, a linear or branched chain lower alkyl N-mono- or N,N-dialkylamino, (linear or branched chain lower alkyl N-mono- or N,N-dialkylamino)(lower alkyl), halogen, cyano, trifluoromethyl, nitro, aryl or heteroaryl; or a salt thereof, and a pharmaceutically acceptable carrier or diluent. Also disclosed are methods of inhibiting bacterial growth, comprising the administration of formulations comprising the compounds of formulas (I) to (V).

公开(公告)号：US20120021519A1

公开(公告)日：2012-01-26

申请号：US13119848

申请日：2009-09-21

申请人： Justin Ichida ,  Joel Blanchard ,  Lee Rubin ,  Kevin Eggan ,  Kelvin Lam

发明人： Justin Ichida ,  Joel Blanchard ,  Lee Rubin ,  Kevin Eggan ,  Kelvin Lam

IPC分类号： C12N5/071

CPC分类号： C12N5/0696 ,  C12N2501/065 ,  C12N2501/15 ,  C12N2501/603 ,  C12N2501/604 ,  C12N2501/606 ,  C12N2501/727 ,  C12N2501/999

摘要： The disclosure features a method of producing a reprogrammed cell (e.g. an induced pluripotent stem cell or an undifferentiated cell) from a differentiated (e.g. somatic) cell. In some embodiments, the methods includes contacting a differentiated (e.g. somatic cell) with a TGFBR1 inhibitor or anti-TGF-β-antibody to produce a reprogrammed cell (e.g. pluripotent stem cell or undifferentiated cell). Embodiments of the present invention relate to a reprogrammed cell and methods and compositions for producing a chemically produced reprogrammed cell or populations thereof.

摘要翻译： 本公开特征在于从分化（例如体细胞）细胞产生重编程细胞（例如，诱导多能干细胞或未分化细胞）的方法。 在一些实施方案中，所述方法包括使分化的（例如体细胞）与TGFBR1抑制剂或抗TGF-β抗体接触以产生重编程细胞（例如多能干细胞或未分化细胞）。 本发明的实施方案涉及重编程细胞以及用于产生化学产生的重编程细胞或其群体的方法和组合物。

公开(公告)号：US07418695B2

公开(公告)日：2008-08-26

申请号：US10888275

申请日：2004-07-09

申请人： Kelvin Lam ,  Susan Cohan ,  Melissa A. Borza

发明人： Kelvin Lam ,  Susan Cohan ,  Melissa A. Borza

IPC分类号： G06F9/45

CPC分类号： G06F9/44505

摘要： Methods, systems, apparatus and computer-readable media are disclosed for providing cross-platform software dependency information. A first exemplary method is disclosed that includes receiving a request for software dependency information relating to a number of platforms. The method also includes identifying a set of applications, each application corresponding to a one of the set of platforms. The method further includes transmitting to each of the identified applications a platform-specific software dependency query. A response to each platform-specific software dependency query is received from each of the identified applications, and the are combined into a combined query result. The method still further includes transmitting the combined query result containing the software dependency information in response to the initial query. Other methods, apparatus, systems and computer readable media are disclosed for presenting cross-platform software dependency information.

摘要翻译： 公开了用于提供跨平台软件依赖性信息的方法，系统，装置和计算机可读介质。 公开了第一示例性方法，其包括接收与多个平台相关的软件依赖性信息的请求。 该方法还包括识别一组应用程序，每个应用程序对应于一组平台中的一个。 该方法还包括向每个所识别的应用程序发送平台特定的软件依赖性查询。 从每个识别的应用程序接收到对每个平台特定的软件依赖性查询的响应，并将它们组合成组合的查询结果。 该方法还包括响应于初始查询发送包含软件依赖性信息的组合查询结果。 公开了用于呈现跨平台软件依赖性信息的其它方法，装置，系统和计算机可读介质。

公开(公告)号：US06194399B1

公开(公告)日：2001-02-27

申请号：US09413409

申请日：1999-10-06

申请人： Kelvin Lam ,  Yi Bin Xiang

发明人： Kelvin Lam ,  Yi Bin Xiang

IPC分类号： A61K3163

CPC分类号： A61K31/63 ,  A61K31/135 ,  A61K31/138 ,  A61K31/495

摘要： Disclosed are pharmaceutical compositions and formulations comprising the compound: wherein: (a) R1, R2, R3, and R4 are independently selected from the group consisting of hydrogen, or optionally substituted alkyl, aryl, vinyl, alkyl(aryl), vinyl(aryl), amine, amide; or at least one of R1 and R2, together, and R3 and R4, together, form an optionally substituted ring system, wherein the ring system is optionally interrupted by at least one heteroatom; (b) X is hydrogen, NO2, CN, halogen, OH, SO2, alkyl, alkoxy, or vinyl; and (c) wherein when R1, R2, R3, and R4 are alkyl, aryl, vinyl, alkyl(aryl), vinyl(aryl), amine or amide, R1, R2, R3, and R4 are optionally interrupted with at least one heteroatom, or a salt thereof; and a pharmaceutically acceptable carrier or diluent. Also disclosed are methods of inhibiting microbial replication and treating microbial infections, comprising administration of a pharmaceutical composition or formulation of the invention.

摘要翻译： 公开了包含该化合物的药物组合物和制剂：其中：（a）R 1，R 2，R 3和R 4独立地选自氢或任选取代的烷基，芳基，乙烯基，烷基（芳基），乙烯基 ），胺，酰胺; 或R 1和R 2中的至少一个在一起，并且R 3和R 4一起形成任选取代的环系，其中所述环系统任选被至少一个杂原子中断;（b）X是氢，NO 2，CN，卤素 ，OH，SO 2，烷基，烷氧基或乙烯基; 芳基，乙烯基，芳基，胺或酰胺，R1，R2，R3和R4任选地被至少一个 杂原子或其盐; 和药学上可接受的载体或稀释剂。 还公开了抑制微生物复制和治疗微生物感染的方法，包括施用本发明的药物组合物或制剂。

公开(公告)号：US20130259842A1

公开(公告)日：2013-10-03

申请号：US13698170

申请日：2011-05-18

申请人： Lee Rubin ,  Joel Blanchard ,  Kelvin Lam

发明人： Lee Rubin ,  Joel Blanchard ,  Kelvin Lam

IPC分类号： C12N5/071 ,  C12N5/0793 ,  C12N15/85 ,  A61K35/54 ,  C12Q1/68

CPC分类号： C12N5/0696 ,  A61K35/545 ,  C12N5/0619 ,  C12N5/0657 ,  C12N15/85 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2501/604 ,  C12N2501/606 ,  C12N2506/13 ,  C12N2510/00 ,  C12Q1/6809

摘要： The present invention relates to a stable pluripotent reprogrammed cells, and compositions and methods of isolation and uses thereof, wherein the stable pluripotent reprogrammed cells is derived from a somatic cell and has undergone incomplete remodeling of the epigenome. In some embodiments, the stable reprogrammed cell is a human stable reprogrammed cell. In some embodiments, the stable reprogrammed cell has a statistically significant lower level of expression of one or any combination of Nanog, Dnmt3b, Lefty2 as compared to an induced pluripotent stem cell. In some embodiments, the stable reprogrammed cell has a statistically significant higher level of expression of one or any combination of Tdgf1, Tert or endogenous Sox2 as compared to a somatic cell from which it was derived. In some embodiments, the stable reprogrammed cell has a statistically significant faster rate of doubling as compared to an induced pluripotent stem cell (iPSC) or an embryonic stem (ES) cell. Other aspects of the invention relate to compositions comprising the reprogrammed cell, method of isolation and method of use.

摘要翻译： 本发明涉及稳定的多能重编程细胞，以及其分离及其用途的组合物和方法，其中所述稳定多能重编程细胞衍生自体细胞，并且已经进行表观遗传学的不完全重塑。 在一些实施方案中，稳定的重编程细胞是人稳定的重编程细胞。 在一些实施方案中，与诱导的多能干细胞相比，稳定的重编程细胞具有统计学上显着的较低水平的Nanog，Dnmt3b，Lefty2的一种或任何组合的表达。 在一些实施方案中，稳定的重编程细胞与其衍生的体细胞相比具有统计学上显着更高水平的Tdgf1，Tert或内源性Sox2的一种或任何组合的表达。 在一些实施方案中，与诱导的多能干细胞（iPSC）或胚胎干（ES）细胞相比，稳定的重编程细胞具有统计上显着更快的倍增速率。 本发明的其它方面涉及包含重编程细胞，分离方法和使用方法的组合物。

公开(公告)号：US08219541B2

公开(公告)日：2012-07-10

申请号：US12607745

申请日：2009-10-28

申请人： Richard Kevin Magnuson ,  Stephen J. Siwek ,  Kelvin Lam ,  Rashmi Rekha Sahoo ,  A. V. S. S. N. S. Sudhakar ,  David Andrew Tootill

发明人： Richard Kevin Magnuson ,  Stephen J. Siwek ,  Kelvin Lam ,  Rashmi Rekha Sahoo ,  A. V. S. S. N. S. Sudhakar ,  David Andrew Tootill

IPC分类号： G06F7/00

CPC分类号： G06Q10/06 ,  G06Q10/04

摘要： A system and method for automatically detecting, reporting, and tracking conflicts in a change management system is provided. In particular, the system and method described herein may be used to identify potential conflicts associated with resources and schedules involved in a proposed change to an information technology infrastructure. A conflict analysis engine may analyze a change order that includes planned changes to an information technology infrastructure to identify potential conflicts associated with the change order that includes the planned changes to the information technology infrastructure. The potential conflicts may then be added to a conflicts list for the change order and a workflow may be created to manage resolving the potential conflicts. Thus, in response to resolving the potential conflicts, the planned changes may be deployed within the information technology infrastructure.

摘要翻译： 提供了一种用于自动检测，报告和跟踪变更管理系统中的冲突的系统和方法。 特别地，本文描述的系统和方法可以用于识别与信息技术基础设施的建议改变中涉及的资源和时间表相关联的潜在冲突。 冲突分析引擎可以分析包括对信息技术基础设施的计划更改的变更顺序，以识别与包含计划的信息技术基础设施变更的变更顺序相关的潜在冲突。 然后可能将潜在的冲突添加到更改顺序的冲突列表中，并且可以创建工作流来管理解决潜在的冲突。 因此，为了解决潜在的冲突，计划的变更可能部署在信息技术基础设施中。

公开(公告)号：US20110070645A1

公开(公告)日：2011-03-24

申请号：US12989284

申请日：2009-04-22

申请人： Shuibing Chen ,  Douglas A. Melton ,  Malgorzata Borowiak ,  Julia Lamenzo ,  Stuart L. Schreiber ,  Lee F. Peng ,  Lance Davidow ,  Kelvin Lam ,  Lee L. Rubin

发明人： Shuibing Chen ,  Douglas A. Melton ,  Malgorzata Borowiak ,  Julia Lamenzo ,  Stuart L. Schreiber ,  Lee F. Peng ,  Lance Davidow ,  Kelvin Lam ,  Lee L. Rubin

IPC分类号： C12N5/071 ,  C12N5/0735

CPC分类号： C12N5/0678 ,  C12N5/0606 ,  C12N5/0676 ,  C12N2501/115 ,  C12N2501/119 ,  C12N2501/16 ,  C12N2501/385 ,  C12N2501/415 ,  C12N2501/42 ,  C12N2501/727 ,  C12N2501/998 ,  C12N2501/999 ,  C12N2506/02

摘要： Certain embodiments disclosed herein are directed to a method of producing pancreatic cells or pancreatic cell precursors by exposing human embryonic stem cells to an effective amount of at least one compound listed in Table I to differentiate the human embryonic stem cells into the pancreatic cells or the pancreatic cell precursors. Kits and pancreatic cell lines produced using the methods are also described.

摘要翻译： 本文公开的某些实施例涉及通过将人胚胎干细胞暴露于有效量的表I所列的至少一种化合物来产生胰腺细胞或胰腺细胞前体的方法，以将人胚胎干细胞分化成胰腺细胞或胰腺细胞 细胞前体。 还描述了使用这些方法生产的试剂盒和胰腺细胞系。